ANXA2 could act as a moderator of EGFR-directed therapy resistance in triple negative breast cancer

Yue Zhang, Jiajia Bi, Hongtao Zhu, Mei Shi, Xianlu Zeng
  • Bioscience Biotechnology and Biochemistry, June 2018, Taylor & Francis
  • DOI: 10.1080/09168451.2018.1484275
The author haven't yet claimed this publicationThe author haven't yet claimed this publication

In partnership with: